The changing landscape of systemic therapy in the treatment of synchronous metastatic hormone-sensitive prostate cancer

医学 醋酸阿比特龙酯 多西紫杉醇 前列腺癌 内科学 癌症 全身疗法 肿瘤科 雄激素剥夺疗法 乳腺癌
作者
Edward Lambert,Nicolaas Lumen,Valerie Fonteyne,Daan De Maeseneer,Sofie Verbeke,Geert Villeirs,Kathia De Man,Charles Van Praet
出处
期刊:Clinical Genitourinary Cancer [Elsevier BV]
标识
DOI:10.1016/j.clgc.2022.11.001
摘要

To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a "real-world" setting and to explore reasons why contemporary standard of care (SOC) was not administrated to the patient.Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction of apalutamide (Time period 4, March 2018-October 2021). For every time period, we evaluated the initiated additional ST. In case patients received treatment that differed from contemporary SOC according to guidelines, reasons for this difference were explored.In total, 243 patients were included. A progressive decline in ADT monotherapy from 85% to 29% over time was observed. The proportion of patients receiving additional STs increased from 34% to 59%. Forty percent of patients were not treated according to contemporary SOC, but this percentage varied strongly per time period (10%, 67%, 53%, and 32% from time period 1 to time period 4 respectively). Reasons for these variations were heterogenous and varied across the 4 time periods. Patients being unfit for treatment and treating physicians failing to consider additional STs were the most prevalent reasons. The proportion of patients unfit for additional ST decreased from 18% to 4% over time.Use of ADT monotherapy declined gradually after the introduction of additional systemic treatments. The proportion of patients unfit for additional ST declined as more treatments became available. Although compliance to SOC increased over time, these real-world data show that adherence to clinical practice guidelines remains suboptimal. Efforts should be made by clinicians to increase the adherence to practice guidelines.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei应助Joefong采纳,获得10
2秒前
Kyle完成签到 ,获得积分10
2秒前
柒月发布了新的文献求助10
2秒前
2秒前
rainy发布了新的文献求助10
3秒前
shw完成签到 ,获得积分10
4秒前
小夏完成签到,获得积分10
6秒前
7秒前
万能图书馆应助大发明家采纳,获得10
8秒前
AishuangQi发布了新的文献求助10
8秒前
9秒前
molihuakai应助自由可兰采纳,获得10
9秒前
李飞feifei发布了新的文献求助10
9秒前
10秒前
瘦瘦稀完成签到,获得积分10
11秒前
12秒前
天天快乐应助chess采纳,获得10
12秒前
一个有点长的序完成签到,获得积分10
12秒前
傻芙芙的完成签到,获得积分10
12秒前
12秒前
张鱼小丸子完成签到,获得积分10
12秒前
俏皮路灯发布了新的文献求助10
13秒前
Echo发布了新的文献求助10
13秒前
yeah发布了新的文献求助10
13秒前
科研通AI6.3应助1111采纳,获得10
16秒前
17秒前
RennyZ发布了新的文献求助10
17秒前
17秒前
17秒前
HXX关闭了HXX文献求助
17秒前
tmrrr发布了新的文献求助10
17秒前
18秒前
18秒前
Akim应助cc采纳,获得10
19秒前
agentwang发布了新的文献求助10
21秒前
SKY完成签到,获得积分10
22秒前
wwwwpy完成签到,获得积分10
22秒前
予光完成签到 ,获得积分10
22秒前
lehua发布了新的文献求助10
24秒前
西西发布了新的文献求助10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6425090
求助须知:如何正确求助?哪些是违规求助? 8242795
关于积分的说明 17524788
捐赠科研通 5479528
什么是DOI,文献DOI怎么找? 2893933
邀请新用户注册赠送积分活动 1870186
关于科研通互助平台的介绍 1708164